ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO07-FR

Kansas PKD Research and Translation Core Center

Session Information

  • Informational Posters - II
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

Authors

  • Calvet, James P., University of Kansas Medical Center, Kansas City, Kansas, United States
  • Ward, Christopher J., University of Kansas Medical Center, Kansas City, Kansas, United States
  • Peterson, Kenneth R., University of Kansas Medical Center, Kansas City, Kansas, United States
  • Wallace, Darren P., University of Kansas Medical Center, Kansas City, Kansas, United States
  • Yu, Alan S.L., University of Kansas Medical Center, Kansas City, Kansas, United States
Description

The Kansas PKD Research and Translation Core Center consists of an Administrative Core, Pilot & Feasibility Grant Program, Educational Enrichment Program and four Biomedical Research Cores related to target identification for PKD therapy development. The mission of the Center is the promotion of research leading to a better understanding of PKD and the discovery of targets for therapy and development of clinical trials to improve patient outcomes. Core 1: The Gene Targeting Core provides expertise on gene editing in Pkd1 hypomorphic mice to discover and validate cellular pathways, interacting proteins and signaling pathways involved in PKD progression. The Core provides a range of gene-editing services and has the capacity to establish at least five new animal models per year and multiple novel cell lines using TALEN and CRISPR methods. Core 2: The Epigenetics and Genomics Core offers a range of reagents and expertise to investigate transcriptional and epigenetic regulators in PKD-related signaling pathways and to discover new therapeutic targets. The Core provides assistance to researchers with analyses including DNA methylation, chromatin immunoprecipitation (ChIP), ChIP-sequencing (ChIP-seq), real-time quantitative PCR gene expression analysis, and provides mouse models for transcriptional and epigenetic regulators. Core 3: The Biomarkers and Biomaterials Core offers blood, urine and urinary exosomes from well-characterized subjects with early-stage PKD, and various biomaterials, including tissue, primary cells and cyst fluid, from PKD kidneys. The goals are to assist investigators in the discovery and validation of biomarkers to monitor the progression of PKD and the response to therapy; to provide human PKD tissues and quality biospecimens; and to assist in the use of PKD cell models to test specific hypotheses and evaluate drug effects. Core 4: The Clinical Research Core is focused on developing and providing clinical trials services and platforms to help investigator-initiated efforts bring new therapeutics to PKD patients. The goal is to facilitate clinical and translational research in PKD through consultative advice on drug development, a patient registry network for clinical trials recruitment, resources and services for conducting clinical trials, and a searchable integrated clinical data repository for observational research.

Funding

  • P30 DK106912